$TDOC
Teladoc Health, Inc. Stock $tdoc

$tdoc Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000147744924000101 Filed on April 26, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$642.4M	$646.1M
YoY Change	-1.53%	2.68%
Cost Of Revenue	$188.1M	$194.5M
YoY Change	-1.3%	2.33%
Gross Profit	$454.4M	$451.6M
YoY Change	-1.62%	2.84%
Gross Profit Margin	70.73%	69.89%
Selling, General & Admin	$160.0M	$166.1M
YoY Change	-10.8%	-51.93%
% of Gross Profit	35.21%	36.77%
Research & Development	$76.75M	$81.39M
YoY Change	-12.09%	-6.43%
% of Gross Profit	16.89%	18.02%
Depreciation & Amortization	$96.57M	$97.89M
YoY Change	27.96%	38.92%
% of Gross Profit	21.25%	21.68%
Operating Expenses	$236.7M	$247.4M
YoY Change	-11.23%	-50.73%
Operating Profit	-$841.1M	-$87.12M
YoY Change	1074.05%	38.17%
Interest Expense	$5.648M	$5.649M
YoY Change	-3.2%	54.85%
% of Operating Profit
Other Income/Expense, Net	-$563.0K	-$370.0K
YoY Change	171.98%	-107.54%
Pretax Income	-$833.8M	-$79.20M
YoY Change	1160.85%	15.54%
Income Tax	$3.884M	$2.690M
% Of Pretax Income
Net Earnings	-$837.7M	-$81.89M
YoY Change	1185.22%	18.29%
Net Earnings / Revenue	-130.39%	-12.67%
Basic Earnings Per Share	-$4.92	-$0.49
Diluted Earnings Per Share	-$4.92	-$0.49
COMMON SHARES
Basic Shares Outstanding	169.6M shares	167.0M shares
Diluted Shares Outstanding	170.2M shares	167.7M shares

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.162B	$1.098B
YoY Change	21.25%	23.56%
Cash & Equivalents	$1.162B	$1.098B
Short-Term Investments
Other Short-Term Assets	$5.837M	$8.534M
YoY Change	-30.25%	-93.74%
Inventory	$34.90M	$32.27M
Prepaid Expenses	$78.25M	$85.48M
Receivables	$218.4M	$214.3M
Other Receivables	$11.54M	$13.56M
Total Short-Term Assets	$1.547B	$1.486B
YoY Change	17.09%	15.51%
LONG-TERM ASSETS
Property, Plant & Equipment	$29.33M	$29.55M
YoY Change	-3.49%	-57.36%
Goodwill	$283.2M	$1.073B
YoY Change	-73.61%	0.0%
Intangibles	$1.547B	$1.614B
YoY Change	-13.26%	-11.11%
Long-Term Investments
YoY Change
Other Assets	$81.43M	$80.01M
YoY Change	11.65%	25.02%
Total Long-Term Assets	$1.977B	$2.834B
YoY Change	-34.0%	-6.22%
TOTAL ASSETS
Total Short-Term Assets	$1.547B	$1.486B
Total Long-Term Assets	$1.977B	$2.834B
Total Assets	$3.524B	$4.321B
YoY Change	-18.37%	0.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$56.11M	$37.67M
YoY Change	249.14%	-2.46%
Accrued Expenses	$228.5M	$196.1M
YoY Change	9.78%	-16.75%
Deferred Revenue	$95.43M	$101.2M
YoY Change	-11.13%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$550.7M
YoY Change
Total Short-Term Liabilities	$930.7M	$388.8M
YoY Change	142.76%	1.97%
LONG-TERM LIABILITIES
Long-Term Debt	$989.7M	$1.540B
YoY Change	-35.61%	-0.3%
Other Long-Term Liabilities	$1.007M	$1.023M
YoY Change	-42.13%	-97.55%
Total Long-Term Liabilities	$1.007M	$1.023M
YoY Change	-42.13%	-99.94%
TOTAL LIABILITIES
Total Short-Term Liabilities	$930.7M	$388.8M
Total Long-Term Liabilities	$1.007M	$1.023M
Total Liabilities	$2.022B	$389.9M
YoY Change	424.9%	-80.68%
SHAREHOLDERS EQUITY
Retained Earnings	-$16.15B	-$15.31B
YoY Change	6.64%	1.55%
Common Stock	$17.69B	$17.64B
YoY Change	1.22%	1.31%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.502B	$2.289B
YoY Change
Total Liabilities & Shareholders Equity	$3.524B	$4.321B
YoY Change	-18.37%	0.27%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	-$837.7M	-$81.89M
YoY Change	1185.22%	18.29%
Depreciation, Depletion And Amortization	$96.57M	$97.89M
YoY Change	27.96%	38.92%
Cash From Operating Activities	$88.68M	$8.920M
YoY Change	-12.35%	-32.2%
INVESTING ACTIVITIES
Capital Expenditures	$27.75M	$1.149M
YoY Change	-24.12%	-97.48%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$27.75M	-$35.51M
YoY Change	-24.12%	-22.16%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.805M	$1.751M
YoY Change	-9.58%	-47.78%
NET CHANGE
Cash From Operating Activities	88.68M	$8.920M
Cash From Investing Activities	-27.75M	-$35.51M
Cash From Financing Activities	3.805M	$1.751M
Net Change In Cash	64.74M	-$24.84M
YoY Change	-5.93%	-14.68%
FREE CASH FLOW
Cash From Operating Activities	$88.68M	$8.920M
Capital Expenditures	$27.75M	$1.149M
Free Cash Flow	$60.94M	$7.771M
YoY Change	-5.69%	-123.93%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1023000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	39971000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	42837000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	15002000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	13623000	usd
CY2024Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	47472000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	49452000	usd
CY2024Q1	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	1539546000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	167000	usd
CY2024Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	17637902000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	17591551000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-15310544000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-15228655000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-38629000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-36990000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	2288898000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	2326073000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4320756000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4392369000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	646131000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	629244000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1080000	usd
CY2023Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	1538688000	usd
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	169314029	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	166658253	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	166658253	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	169000	usd
CY2024Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P9M
CY2024Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2024Q1	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.teladoc.com/20240331#AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.teladoc.com/20240331#AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent
CY2024Q1	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.teladoc.com/20240331#AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	388844000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	420616000	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	169314029	shares
CY2024Q1	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	194538000	usd
CY2023Q1	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	190107000	usd
CY2024Q1	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	183329000	usd
CY2023Q1	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	176790000	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	8911000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	5649000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	5263000	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-370000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4907000	usd
CY2024Q1	us-gaap	Selling Expense SellingExpense	54364000	usd
CY2023Q1	us-gaap	Selling Expense SellingExpense	54490000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	81388000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	86985000	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	111697000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	114145000	usd
CY2024Q1	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	373000	usd
CY2023Q1	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	5944000	usd
CY2024Q1	us-gaap	Restructuring Costs RestructuringCosts	9673000	usd
CY2023Q1	us-gaap	Restructuring Costs RestructuringCosts	8102000	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	95057000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	66860000	usd
CY2024Q1	us-gaap	Depreciation Nonproduction DepreciationNonproduction	2834000	usd
CY2023Q1	us-gaap	Depreciation Nonproduction DepreciationNonproduction	2923000	usd
CY2024Q1	us-gaap	Costs And Expenses CostsAndExpenses	733253000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	706346000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-87122000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-77102000	usd
CY2024Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	13942000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-79199000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-68547000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2690000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	681000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-81889000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-69228000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1639000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1779000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-83528000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-67449000	usd
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.49
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.49
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.42
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.42
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	167730746	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	167730746	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	162922691	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	162922691	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	2326073000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	131000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	46222000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1639000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-81889000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	2288898000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2307745000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	296000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	50634000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1779000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-69228000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	2291226000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-81889000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-69228000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	66860000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	2614000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	3056000	usd
CY2024Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	86000	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	3794000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	42325000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	46038000	usd
CY2024Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-1600000	usd
CY2023Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-355000	usd
CY2024Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1403000	usd
CY2023Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-3244000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2133000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	14046000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	23691000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	6165000	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3091000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-10000000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-1009000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	9939000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-5870000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-9132000	usd
CY2024Q1	tdoc	Increase Decrease In Accrued Liabilities And Other Current Liabilities Excluding Accrued Compensation IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilitiesExcludingAccruedCompensation	25185000	usd
CY2023Q1	tdoc	Increase Decrease In Accrued Liabilities And Other Current Liabilities Excluding Accrued Compensation IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilitiesExcludingAccruedCompensation	15452000	usd
CY2024Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-51973000	usd
CY2023Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-32265000	usd
CY2024Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	7297000	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	5648000	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-2861000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-2858000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-48000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	129000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	8920000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	13156000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1149000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2363000	usd
CY2024Q1	us-gaap	Payments For Software PaymentsForSoftware	34363000	usd
CY2023Q1	us-gaap	Payments For Software PaymentsForSoftware	43261000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-35512000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-45624000	usd
CY2024Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	131000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	296000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	1516000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	2731000	usd
CY2024Q1	tdoc	Cash Related To Tax Withholding For Share Based Compensation Net CashRelatedToTaxWithholdingForShareBasedCompensationNet	106000	usd
CY2023Q1	tdoc	Cash Related To Tax Withholding For Share Based Compensation Net CashRelatedToTaxWithholdingForShareBasedCompensationNet	496000	usd
CY2024Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-2000	usd
CY2023Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-170000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1751000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3353000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-24841000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-29115000	usd
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-899000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-488000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1123675000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	918182000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1097935000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	888579000	usd
CY2024Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-245000	usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	346000	usd
CY2024Q1	us-gaap	Interest Paid InterestPaid	0	usd
CY2023Q1	us-gaap	Interest Paid InterestPaid	194000	usd
CY2024Q1	tdoc	Property And Equipment Net And Intangibles Net Accruals Incurred But Not Yet Paid PropertyAndEquipmentNetAndIntangiblesNetAccrualsIncurredButNotYetPaid	3673000	usd
CY2023Q1	tdoc	Property And Equipment Net And Intangibles Net Accruals Incurred But Not Yet Paid PropertyAndEquipmentNetAndIntangiblesNetAccrualsIncurredButNotYetPaid	5516000	usd
CY2024Q1	tdoc	Deferred Device Cost And Other Current DeferredDeviceCostAndOtherCurrent	34199000	usd
CY2023Q4	tdoc	Deferred Device Cost And Other Current DeferredDeviceCostAndOtherCurrent	32703000	usd
CY2024Q1	tdoc	Deferred Device Cost And Other Noncurrent DeferredDeviceCostAndOtherNoncurrent	17344000	usd
CY2023Q4	tdoc	Deferred Device Cost And Other Noncurrent DeferredDeviceCostAndOtherNoncurrent	17573000	usd
CY2024Q1	tdoc	Deferred Device Cost And Other DeferredDeviceCostAndOther	51543000	usd
CY2023Q4	tdoc	Deferred Device Cost And Other DeferredDeviceCostAndOther	50276000	usd
CY2024Q1	tdoc	Deferred Device Cost And Other Additions DeferredDeviceCostAndOtherAdditions	12239000	usd
CY2024Q1	tdoc	Deferred Device Cost And Other Cost Of Revenue Recognized DeferredDeviceCostAndOtherCostOfRevenueRecognized	10972000	usd
CY2024Q1	tdoc	Deferred Device Cost And Other DeferredDeviceCostAndOther	51543000	usd
CY2023Q1	tdoc	Cloud Computing Expense CloudComputingExpense	800000	usd
CY2024Q1	us-gaap	Nature Of Operations NatureOfOperations	Organization and Description of Business<div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Teladoc Health, Inc., together with its subsidiaries, is referred to herein as “Teladoc Health,” or the “Company,” and is the global leader in whole person virtual care, forging a new healthcare experience with better convenience, outcomes, and value. The Company’s mission is to empower all people everywhere to live their healthiest lives by transforming the healthcare experience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was incorporated in the State of Texas in June 2002 and changed its state of incorporation to the State of Delaware in October 2008. Effective August 10, 2018, Teladoc, Inc. changed its corporate name to Teladoc Health, Inc. The Company’s principal executive office is located in Purchase, New York.</span></div>
CY2024Q1	tdoc	Number Of Professional Associations Consolidated As Variable Interest Entities NumberOfProfessionalAssociationsConsolidatedAsVariableInterestEntities	2	professionalassociation
CY2024Q1	tdoc	Number Of Professional Corporations Consolidated As Variable Interest Entities NumberOfProfessionalCorporationsConsolidatedAsVariableInterestEntities	10	professionalcorporation
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="padding-left:9pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. The Company bases its estimates on historical experience, current business and economic factors, and various other assumptions that the Company believes are necessary to form a basis for making judgments about the carrying values of assets and liabilities, the recorded amounts of revenue and expenses, and the disclosure of contingent assets and liabilities. The Company is subject to uncertainties such as the impact of future events, economic and political factors, and changes in the Company’s business environment; therefore, actual results could differ from these estimates. Accordingly, the accounting estimates used in the preparation of the Company’s condensed consolidated financial statements will change as new events occur, as more experience is acquired, as additional information is obtained and as the Company’s operating environment evolves. The Company believes that estimates used in the preparation of these condensed consolidated financial statements are reasonable; however, actual results could differ materially from these estimates.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in estimates are made when circumstances warrant. Such changes in estimates and refinements in estimation methodologies are reflected in the Condensed Consolidated Statements of Operations; if material, the effects of changes in estimates are disclosed in the Notes to Unaudited Condensed Consolidated Financial Statements. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Significant estimates and assumptions by management affect areas including the value and useful life of long-lived assets (including intangible assets), the capitalization and amortization of software development costs, deferred device and contract costs, allowances for sales and for doubtful accounts, and the accounting for business combinations. Other significant areas include revenue recognition (including performance guarantees), the accounting for income taxes, contingencies, litigation and related legal accruals, the accounting for stock-based compensation awards, and other items as described in Note 2. “Basis of Presentation and Principles of Consolidation" in the Summary of Significant Accounting policies in the 2023 Form 10-K and as may be updated in this Quarterly Report in Note 2. “Basis of Presentation and Principles of Consolidation."</span></div>
CY2024Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="padding-left:9pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified to conform to the current year presentation.</span></div>
CY2023Q4	tdoc	Deferred Device Cost And Other DeferredDeviceCostAndOther	50276000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	646131000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	629244000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	646131000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	629244000	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	109283000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	113786000	usd
CY2024Q1	tdoc	Contract With Customer Liability Additions ContractWithCustomerLiabilityAdditions	63061000	usd
CY2023Q1	tdoc	Contract With Customer Liability Additions ContractWithCustomerLiabilityAdditions	67242000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	56113000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	61697000	usd
CY2024Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	116231000	usd
CY2023Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	119331000	usd
CY2024Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	94000000	usd
CY2024Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	17300000	usd
CY2024Q1	tdoc	Inventory Raw Materials And Purchased Parts Gross InventoryRawMaterialsAndPurchasedPartsGross	11529000	usd
CY2023Q4	tdoc	Inventory Raw Materials And Purchased Parts Gross InventoryRawMaterialsAndPurchasedPartsGross	9338000	usd
CY2024Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	678000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	299000	usd
CY2024Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	20061000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	19876000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	32268000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	29513000	usd
CY2024Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	85477000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	65651000	usd
CY2024Q1	tdoc	Deferred Device Cost And Other Current DeferredDeviceCostAndOtherCurrent	34199000	usd
CY2023Q4	tdoc	Deferred Device Cost And Other Current DeferredDeviceCostAndOtherCurrent	32703000	usd
CY2024Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	13559000	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	12640000	usd
CY2024Q1	us-gaap	Other Assets Current OtherAssetsCurrent	8534000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	7443000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	141769000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	118437000	usd
CY2024Q1	us-gaap	Goodwill Goodwill	1073190000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	1073190000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2614065000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	999827000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1614238000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2584733000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	906952000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1677781000	usd
CY2024Q1	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	30876000	usd
CY2023Q1	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	16601000	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	95057000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	66860000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	272784000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	280727000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	223039000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	163836000	usd
CY2024Q1	tdoc	Finite Lived Intangible Asset Expected Amortization Year Four And Thereafter FiniteLivedIntangibleAssetExpectedAmortizationYearFourAndThereafter	673852000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1614238000	usd
CY2024Q1	tdoc	Cloud Computing Costs Net CloudComputingCostsNet	42000000	usd
CY2023Q4	tdoc	Cloud Computing Costs Net CloudComputingCostsNet	41100000	usd
CY2024Q1	tdoc	Cloud Computing Expense CloudComputingExpense	1200000	usd
CY2024Q1	tdoc	Revenue From Contract With Customer Performance Guarantees Current RevenueFromContractWithCustomerPerformanceGuaranteesCurrent	36282000	usd
CY2023Q4	tdoc	Revenue From Contract With Customer Performance Guarantees Current RevenueFromContractWithCustomerPerformanceGuaranteesCurrent	36934000	usd
CY2024Q1	tdoc	Accrued Marketing And Advertising Current AccruedMarketingAndAdvertisingCurrent	38724000	usd
CY2023Q4	tdoc	Accrued Marketing And Advertising Current AccruedMarketingAndAdvertisingCurrent	34427000	usd
CY2024Q1	tdoc	Accrued Consulting And Customer Service Fees Current AccruedConsultingAndCustomerServiceFeesCurrent	16443000	usd
CY2023Q4	tdoc	Accrued Consulting And Customer Service Fees Current AccruedConsultingAndCustomerServiceFeesCurrent	16416000	usd
CY2024Q1	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	12931000	usd
CY2023Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	12933000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	10744000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	10752000	usd
CY2024Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	10137000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	9910000	usd
CY2024Q1	tdoc	Accrued Information Technology Expense Current AccruedInformationTechnologyExpenseCurrent	7968000	usd
CY2023Q4	tdoc	Accrued Information Technology Expense Current AccruedInformationTechnologyExpenseCurrent	7605000	usd
CY2024Q1	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	6530000	usd
CY2023Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	5777000	usd
CY2024Q1	us-gaap	Interest Payable Current InterestPayableCurrent	5812000	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1481000	usd
CY2024Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	4127000	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	621000	usd
CY2024Q1	tdoc	Other Current Liabilities Staff Augmentation OtherCurrentLiabilitiesStaffAugmentation	3532000	usd
CY2023Q4	tdoc	Other Current Liabilities Staff Augmentation OtherCurrentLiabilitiesStaffAugmentation	4287000	usd
CY2024Q1	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	3489000	usd
CY2023Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	3800000	usd
CY2024Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	42699000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	33691000	usd
CY2024Q1	tdoc	Accrued Liabilities And Other Liabilities Excluding Accrued Compensation Current AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent	199418000	usd
CY2023Q4	tdoc	Accrued Liabilities And Other Liabilities Excluding Accrued Compensation Current AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent	178634000	usd
CY2024Q1	tdoc	Debt Instrument Number Of Series Of Convertible Senior Debt Outstanding DebtInstrumentNumberOfSeriesOfConvertibleSeniorDebtOutstanding	3	debtseries
CY2024Q1	us-gaap	Convertible Debt ConvertibleDebt	1539546000	usd
CY2023Q4	us-gaap	Convertible Debt ConvertibleDebt	1538688000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	9979000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	12260000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	11101000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	8088000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	5918000	usd
CY2024Q1	tdoc	Lessee Operating Lease Liability Payments Due Year Five And After Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive	12985000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	60331000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	9616000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	50715000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	10744000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	39971000	usd
CY2024Q1	us-gaap	Restructuring Costs RestructuringCosts	9700000	usd
CY2023Q1	us-gaap	Restructuring Costs RestructuringCosts	8100000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	8768512	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4182187	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	27.37
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y3M3D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	13732000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	32477	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	20.66
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	24072	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	5.45
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	291000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	148705	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	39.78
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4041887	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	27.13
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y9M
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	5669000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	4041887	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	27.13
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P4Y9M
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	5669000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3274003	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	26.43
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y9M29D
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	5669000	usd
CY2024Q1	tdoc	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Total Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue	400000	usd
CY2023Q1	tdoc	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Total Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue	200000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.6786
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.6794
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.6558
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0385
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0390
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0407
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	42325000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	46038000	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	3897000	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	4596000	usd
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	46222000	usd
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	50634000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2700000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	700000	usd
CY2024Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	646131000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	629244000	usd
CY2024Q1	tdoc	Earnings Before Interest Taxes Depreciation And Amortization EarningsBeforeInterestTaxesDepreciationAndAmortization	63140000	usd
CY2023Q1	tdoc	Earnings Before Interest Taxes Depreciation And Amortization EarningsBeforeInterestTaxesDepreciationAndAmortization	52765000	usd
CY2024Q1	tdoc	Earnings Before Interest Taxes Depreciation And Amortization EarningsBeforeInterestTaxesDepreciationAndAmortization	63140000	usd
CY2023Q1	tdoc	Earnings Before Interest Taxes Depreciation And Amortization EarningsBeforeInterestTaxesDepreciationAndAmortization	52765000	usd
CY2024Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	13942000	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	8911000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	5649000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	5263000	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-370000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4907000	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	95057000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	66860000	usd
CY2024Q1	us-gaap	Depreciation Nonproduction DepreciationNonproduction	2834000	usd
CY2023Q1	us-gaap	Depreciation Nonproduction DepreciationNonproduction	2923000	usd
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	42325000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	46038000	usd
CY2024Q1	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	373000	usd
CY2023Q1	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	5944000	usd
CY2023Q1	us-gaap	Restructuring Costs RestructuringCosts	8102000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-79199000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-68547000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2690000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	681000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-81889000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-69228000	usd
CY2024Q1	us-gaap	Noncurrent Assets NoncurrentAssets	29550000	usd
CY2023Q4	us-gaap	Noncurrent Assets NoncurrentAssets	32032000	usd
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false

Files In Submission

Name	View Source	Status
0001477449-24-000101-index-headers.html	Edgar Link	pending
0001477449-24-000101-index.html	Edgar Link	pending
0001477449-24-000101.txt	Edgar Link	pending
0001477449-24-000101-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tdoc-20240331.htm	Edgar Link	pending
tdoc-20240331.xsd	Edgar Link	pending
tdoc-20240331xexx101.htm	Edgar Link	pending
tdoc-20240331xexx102.htm	Edgar Link	pending
tdoc-20240331xexx103.htm	Edgar Link	pending
tdoc-20240331xexx104.htm	Edgar Link	pending
tdoc-20240331xexx311.htm	Edgar Link	pending
tdoc-20240331xexx321.htm	Edgar Link	pending
tdoc-20240331_def.xml	Edgar Link	unprocessable
tdoc-20240331_pre.xml	Edgar Link	unprocessable
tdoc-20240331_htm.xml	Edgar Link	completed
tdoc-20240331_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
tdoc-20240331_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TDOC
Teladoc Health, Inc. Stock $tdoc

2024 Q2 Form 10-Q Financial Statement

#000147744924000101 Filed on April 26, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TDOC Teladoc Health, Inc. Stock $tdoc

2024 Q2 Form 10-Q Financial Statement

#000147744924000101 Filed on April 26, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TDOC
Teladoc Health, Inc. Stock $tdoc